Neuroparacoccidioidomycosis

Shilpa S Kulkarni; Rustom S Wadia; Datta Kharawade; Mrunal Nandedkar; Neeta Munshi; Prachee Sathe

doi:10.59556/japi.72.0318

Neuroparacoccidioidomycosis

J Assoc Physicians India. 2024 Jun;72(6):99-102. doi: 10.59556/japi.72.0318.

Authors

Shilpa S Kulkarni¹, Rustom S Wadia², Datta Kharawade³, Mrunal Nandedkar⁴, Neeta Munshi⁵, Prachee Sathe⁶

Affiliations

¹ HOD, Intensive Care Unit, Ruby Hall Clinic, Wanowrie, Maharashtra, India, Corresponding Author.
² Consultant Neurologist, Department of Medicine, Ruby Hall Clinic, Pune, Maharashtra, India.
³ Registrar Medicine, Department of Medicine, Ruby Hall Clinic, Pune, Maharashtra, India.
⁴ Consultant Microbiologist, Department of Microbiology and Pathology, Ruby Hall Clinic, Pune, Maharashtra, India.
⁵ Director Pathology Lab, Department of Microbiology and Pathology, Ruby Hall Clinic, Pune, Maharashtra, India.
⁶ Director ICU, Department of Intensive Care Unit, Ruby Hall Clinic, Pune, Maharashtra, India.

PMID: 38881144
DOI: 10.59556/japi.72.0318

Abstract

Paracoccidioidomycosis (PCM) is caused by a dimorphic fungus Paracoccidioides Brasiliensis and is endemic to subtropical areas of Central and South America. CNS involvement of PCM is extremely variable. NeuroPCM is found in 9.65% to 27.18% of PCM cases .Most neuro PCM patients presents with simultaneous involvement of other organ but isolated or initial CNS involvement may be a feature in 21%. Here we report a case of CNS PCM and this appears to be first reported case of PCM and CNS PCM in India.

Publication types

Case Reports

MeSH terms

Adult
Antifungal Agents / therapeutic use
Central Nervous System Fungal Infections / diagnosis
Central Nervous System Fungal Infections / microbiology
Humans
Magnetic Resonance Imaging
Male
Paracoccidioidomycosis* / diagnosis
Paracoccidioidomycosis* / drug therapy

Substances

Antifungal Agents